Hasse et al. (2014) reported that CPT may reduce the risk of TB in ART-naive persons and, there was also a trend of a protective effect even among patients on ART. Therefore, routine CPT should be administered to all HIV-infected people with active-TB disease regardless of CD4 cell count (WHO, 2014). This evidence concerns the gene CD4 and tuberculosis.